News | July 22, 2024
dsm-firmenich to sell MEG-3 fish oil business to KD Pharma Group
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
The pilot plant is focused on scaling up beverage production and will support applications
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The partners also aim to expand their work to Latin America for the first time
The price increases are due to the rising costs of raw materials.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
These re-agent and diagnostic test kits come with 99.7% accuracy
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Subscribe To Our Newsletter & Stay Updated
